Ascentage Pharma Announces Purchase of 100,000 Shares by Trustee for 2022 RSU Scheme

On May 27, 2026, Ascentage Pharma Group International filed a Form 6-K reporting the purchase of common shares by a trustee for its 2022 Restricted Share Unit (RSU) Scheme. The Trustee purchased a total of 100,000 existing shares on-market to satisfy future RSU vesting requirements. The transaction was executed at an average price of approximately HK$39.77 per share, for a total consideration of HK$3,977,000 (excluding transaction costs). The purchased shares represent approximately 0.0268% of the company's total issued shares as of the announcement date. Following this transaction, the total number of existing shares purchased on-market and held by the Trustee for the 2022 RSU Scheme has reached 2,265,000 shares. Under the terms of the trust deed, the Trustee is prohibited from exercising voting rights associated with these held shares. This voluntary announcement follows a series of previous disclosures regarding the adoption, amendment, and granting of awards under the company's equity incentive framework.